MindBio Therapeutics Corp. (CSE: MBIO)

Market Cap	2.70M
Revenue (ttm)	n/a
Net Income (ttm)	-256.36K
Shares Out	135.05M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,000
Open	0.0200
Previous Close	0.0200
Day's Range	0.0200 - 0.0200
52-Week Range	0.0150 - 0.0850
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About MindBio Therapeutics

MindBio Therapeutics Corp., together with its subsidiaries, operates as a clinical stage drug development company in Australasia. The company engages in researching, developing, and testing microdosing of psychedelic substances as a potential treatment for the management of various mental health conditions, such as depression, anxiety, chronic pain, cognitive impairment, post-traumatic stress disorder, panic disorder, and opiate addictions. It also establishes and executes research protocols through formal clinical trials that are facilitated v...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: MBIO

Financial Performance

Financial numbers in AUD